It's a principle that applies across our entire catalog, from metabolic peptides like AOD9604 to neuroregenerative compounds like Cerebrolysin
Our guide to the difference between tirzepatide and retatrutide covers how the addition of glucagon receptor agonism changes the metabolic and longevity profile
Both trials demonstrated dose-dependent efficacy that appeared competitive with injectable GLP-1 agonists (see our drug comparison hub), a finding that electrified the pharmaceutical industry and investor community
On average, patients using Tirzepatide can expect to lose between 15% to 20% of their starting body weight over a period of about 72 weeks, depending on the dosage and adherence to their treatment plan
Some researchers adjust timing or escalation speed based on body weight
By accessing this content, you acknowledge and agree to use the information responsibly, with the expectation that it will support legitimate research and academic investigation only